AVDL

Avadel Pharmaceuticals PLC

AVDL.US avadel.com + Research + Basket
CIK 0001012477
ISIN IE00BDGMC594
CUSIP 338488109
Employees 188
Phone 353 1 901 5201
Fiscal year end December
IPO Jun 07, 1996
Address 10 Earlsfort Terrace, Dublin, Ireland, D02 T380
Price N/A
USD · NASDAQ
52-week range
18.68
23.57
Market Cap
2.12B
P/E Ratio
0.00
Forward P/E
16.86
Book Value
1.01
Div. Yield
N/A
% Institutions
86.80%
% Insiders
1.13%

1 Year

+140.4%

3 Year

+167.5%

10 Year

+131.2%
Description

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland. As of February 12, 2026, Avadel Pharmaceuticals plc operates as a subsidiary of Alkermes plc.

Actions

Add an action for AVDL.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. Gregory J. Divis Jr. CEO & Director 1967
Mr. Thomas S. McHugh Senior VP, Principal Financial & Accounting Officer and CFO 1965
Mr. Jerad G. Seurer General Counsel, Company Secretary & Compliance Officer 1974
Ms. Susan Rodriguez Chief Operating Officer 1965
Mr. Gregory J. Davis VP of Corporate and Business Development 1965
Ms. Angie Woods Vice President of People & Culture NA
Dr. Jason M. Vaughn Ph.D., R.Ph. Senior Vice President of Technical Operations NA
Ms. Jennifer Gudeman PharmD Senior Vice President of Medical & Clinical Affairs NA
Dr. Polly A. Murphy D.V.M., M.B.A., Ph.D. Chief Business Officer 1965
Ms. Marla Scarola M.S. Senior Vice President of Regulatory & Quality NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Jan 21, 2025 Linda Palczuk N/A Purchase 5.00K $7.93 $39.65K SEC
Jan 13, 2025 Peter J Thornton N/A Purchase 10.00K $8.04 $80.40K SEC
Dec 13, 2024 Thomas S Mchugh N/A Purchase 2.30K $10.44 $24.01K SEC
Dec 11, 2024 Thomas S Mchugh N/A Purchase 5.00K $10.49 $52.45K SEC
Dec 10, 2024 Geoffrey Michael Glass N/A Purchase 20.28K $9.84 $199.55K SEC
Dec 09, 2024 Gregory J Divis N/A Purchase 402.00 $9.82 $3.95K SEC
Dec 06, 2024 Gregory J Divis N/A Purchase 9.60K $9.98 $95.79K SEC
Dec 06, 2024 Linda Palczuk N/A Purchase 3.00K $10.19 $30.57K SEC
Jan 16, 2024 Thomas S Mchugh N/A Purchase 2.00K $14.50 $29.00K SEC
Dec 28, 2023 Mark Anthony Mccamish N/A Sale 75.00K $14.53 $1.09M SEC
Aug 14, 2023 Thomas S Mchugh N/A Purchase 2.00K $14.45 $28.90K SEC
Aug 10, 2023 Geoffrey Michael Glass N/A Purchase 14.00K $13.40 $187.60K SEC
Aug 10, 2023 Gregory J Divis N/A Purchase 10.00K $13.20 $132.00K SEC
May 09, 2023 Linda Palczuk N/A Purchase 2.50K $14.76 $36.90K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
HHG PLC 7.43M Sep 30, 2025 7.57% $0.05 -33.26%
BlackRock Inc 6.97M Sep 30, 2025 7.11% $0.00 2.50%
Vanguard Group Inc 5.86M Dec 31, 2025 5.98% $0.00 4.61%
Gendell Jeffrey L 4.77M Dec 31, 2025 4.86% $1.79 -10.26%
Weiss Asset Management LP 4.52M Dec 31, 2025 4.60% $1.36 0.00%
Test Hedge Fund Mgmt 3.86M Dec 31, 2025 3.93% $3.85 0.00%
Tudor Investment Corp Et AL 2.98M Dec 31, 2025 3.04% $0.12 6,717.65%
Fidelity International Ltd 2.82M Dec 31, 2025 2.88% $0.05 0.00%
Vivo Capital, LLC 2.68M Dec 31, 2025 2.73% $3.74 0.00%
State Street Corp 2.29M Sep 30, 2025 2.34% $0.00 10.68%
Morgan Stanley - Brokerage Accounts 2.26M Sep 30, 2025 2.30% $0.00 89.39%
Geode Capital Management, LLC 2.16M Dec 31, 2025 2.20% $0.00 -0.89%
Highbridge Capital Management, LLC 2.05M Dec 31, 2025 2.09% $1.41 0.00%
WEALTH EFFECTS LLC 1.89M Dec 31, 2025 1.93% $12.75 -17.34%
Pentwater Capital Management LP 1.68M Dec 31, 2025 1.72% $0.19 0.00%
Bank of America Corp 1.34M Sep 30, 2025 1.36% $0.00 828.18%
Kennedy Capital Management Inc 1.19M Dec 31, 2025 1.22% $0.55 -26.59%
JPMorgan Chase & Co 1.13M Sep 30, 2025 1.15% $0.00 910.77%
Water Island Capital LLC 1.09M Dec 31, 2025 1.11% $2.53 0.00%
Northern Trust Corp 856.84K Sep 30, 2025 0.87% $0.00 2.11%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 iShares Russell 2000 ETF 2.19M 2.23% ▲ 0.00% Feb 10, 2026
2 Janus Henderson US Small Cap Growth MA 1.44M 1.47% ▲ 0.00% Sep 30, 2025
3 Amundi Tiedemann Arbitrage Strat I USD 1.34M 1.36% ▲ 63.41% Nov 30, 2025
4 Arbitrage R 957.44K 0.98% ▲ 0.00% Nov 30, 2025
5 Fidelity Small Cap Index 875.95K 0.89% ▼ 2.80% Dec 31, 2025
6 iShares Russell 2000 Growth ETF 749.39K 0.76% ▲ 0.00% Feb 10, 2026
7 Fidelity Canadian Large Cap Sr B 740.00K 0.75% ▲ 0.00% Dec 31, 2025
8 Kennedy Small Cap Select 682.57K 0.70% ▲ 8.80% Dec 31, 2025
9 SEB Läkemedelsfond 664.58K 0.68% ▲ 20.72% Sep 30, 2025
10 DWS Small Cap Core S 568.88K 0.58% ▲ 0.00% Jan 31, 2026

Financial Highlights

▼
Market Cap: $2.12B
EBITDA: $2.70M
P/E Ratio: $0.00
PEG Ratio: $0.07
Book Value: $1.01
Earnings/Share: $0.00
Profit Margin: -0.11%
Operating Margin: 2.50%
ROA (TTM): -0.34%
ROE (TTM): -0.32%
Revenue (TTM): $248.52M
Revenue/Share (TTM): $2.57
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 54.90%

Valuation Metrics

Enterprise Value: $2.03B
Trailing P/E: 0.00
Forward P/E: 16.86

Shares Statistics

Shares Outstanding: 98.15M
Shares Float: 91.56M
% Insiders: 1.13%
% Institutions: 86.80%
Shares Short: 2.31M
Shares Short (Prior Month): 3.61M
Short Ratio: 1.60
Short % Float: 2.38%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$169.12M
Cost of Goods Sold
adjust
$-15.28M
Gross Profit
subtotal
$153.84M
SG&A
adjust
$-181.04M
R&D
adjust
$-15.20M
Operating Income
subtotal
$-42.40M
Other / Non-Operating Items
adjust
$-6.43M
Net Income
subtotal
$-48.83M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about AVDL.US!